Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genentech : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients

10/15/2021 | 11:05am EST

By Stephen Nakrosis

Genentech on Friday said the Food and Drug Administration approved its Tencentriq as an adjuvant treatment for certain lung cancer patients.

The company said Tencentriq, or atezolizumab, was approved as adjuvant treatment following surgery and platinum-based chemotherapy for certain adults with Stage II-IIIA non-small cell lung cancer.

Genentech said Tecentriq is the first and only cancer immunotherapy available for adjuvant treatment of NSCLC.

The company said the approval was based on results from interim analysis of the Phase III IMpower010 study, which showed treatment with Tecentriq improved disease-free survival by over one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with the best supportive care.

Genentech is a member of the Roche Group.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

10-15-21 1305ET

All news about ROCHE HOLDING AG
12/03PAUL BULCKE : Roche says Nestle Chairman Bulcke to leave its board of directors
RE
12/03Roche to Name New Member to Board of Directors, Re-Elect Chairman
DJ
12/03ROCHE : Änderungen im Verwaltungsrat von Roche
PU
12/03Changes in the Board of Directors
AQ
12/03Roche Holding Ltd Announces Paul Bulcke Will Not to Stand for Re-Election to Its Board ..
CI
12/03REMINDER : Invitation to Roche's virtual analyst event during ESMO IO
PU
12/03Roche develops new research test kits for Omicron variant
RE
12/03Roche Unveils Three Testing Kits to Identify Omicron Variant Mutations
MT
12/03Roche develops new test kits for COVID-19 Omicron variant
RE
12/03Roche has rapidly developed additional testing options to differentiate mutations in th..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 134 M 67 688 M 67 688 M
Net income 2021 15 273 M 16 638 M 16 638 M
Net cash 2021 4 368 M 4 759 M 4 759 M
P/E ratio 2021 19,7x
Yield 2021 2,57%
Capitalization 314 B 341 B 342 B
EV / Sales 2021 4,98x
EV / Sales 2022 4,87x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 362,25 CHF
Average target price 388,44 CHF
Spread / Average Target 7,23%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG17.62%341 364
JOHNSON & JOHNSON1.27%419 583
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641
ABBVIE INC.8.18%210 113